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Advances in single-cell antibody cloning methods have led to the
identiﬁcation of a variety of broadly neutralizing anti–HIV-1 anti-
bodies. We developed a computational tool (Antibody Database) to
help identify critical residues on the HIV-1 envelope protein whose
natural variation affects antibody activity. Our simplifying assump-
tion was that, for a given antibody, a signiﬁcant portion of the
dispersion of neutralization activity across a panel of HIV-1 strains
is due to the amino acid identity or glycosylation state at a small
number of speciﬁc sites, each acting independently. A model of an
antibody’s neutralization IC50 was developed in which each site
contributes a term to the logarithm of the modeled IC50. The anal-
ysis program attempts to determine the set of rules that minimizes
the sum of the residuals between observed and modeled IC50 val-
ues. The predictive quality of the identiﬁed rules may be assessed
in part by whether there is support for rules within individual viral
clades. As a test case, we analyzed antibody 8ANC195, an anti-
glycoprotein gp120 antibody of unknown speciﬁcity. The model
for this antibody indicated that several glycosylation sites were
critical for neutralization. We evaluated this prediction by measur-
ing neutralization potencies of 8ANC195 against HIV-1 in vitro and
in an antibody therapy experiment in humanized mice. These ex-
periments conﬁrmed that 8ANC195 represents a distinct class of
glycan-dependent anti–HIV-1 antibody and validated the utility of
computational analysis of neutralization panel data.
Identifying the epitope for a neutralizing antibody is essential tounderstanding its activity and to structural approaches to vac-
cine development. Advances in methods for antibody isolation
and cloning have led to the discovery of many broadly neutralizing
antibodies against the HIV-1 (1–5) and inﬂuenza (6, 7) envelope
(Env) glycoproteins. Initial characterization of these antibodies
often involves measurement of their neutralization activity against
a panel of viruses, but such experiments do not generally lead to
conclusive identiﬁcation of an antibody’s epitope. Common meth-
ods for determining antibody epitopes include peptide scanning,
competition experiments with known ligands, X-ray crystallogra-
phy of antibody–antigen complexes, and mutagenesis experiments
(8). Newer methods include phylogenetically corrected statistical
analysis (9) and screening of cell surface-displayed mutant anti-
gen libraries (10). A related problem to deducing critical residues
on Env for the neutralization activity of particular antibodies is
the relationship between viral sequences and sensitivity to small
molecule antiretroviral drugs. A number of computational methods
for predicting the sensitivity to antiretroviral drugs from patient
viral sequence data have been developed (11, 12); by analogy, it
may be possible to use relationships between Env sequences and
neutralization data to extract information about antibody epitopes.
Neutralizing activities of antibodies against HIV-1 are routinely
evaluated against a panel of pseudoviruses that express distinct
Env proteins (13). The pseudoviruses are generated by cotrans-
fection of an Env-expressing vector and a replication-incompetent
backbone plasmid. Neutralization is assessed by measuring the
reduction in infectivity as function of concentration of a potential
inhibitor. In vitro neutralization results for a given strain of HIV-1
are characterized by an IC50 value, the concentration at which
infectivity is reduced by 50% (13). The variation in activity across
a panel is a complicated function of Env sequence that reﬂects
several factors including the binding afﬁnity of the antibody for
that Env protein, the intrinsic infection kinetics of the viral strain,
the pseudovirus stability, and the degree of exposure of the anti-
body epitope at various time points during the viral fusion process
(14, 15). Although manual inspection of neutralization panel data
with viral sequence alignments may suggest candidate residues for
mutagenesis studies, we wanted to analyze neutralization data with
a systematic approach to better understand how Env sequence
affects neutralization potency. We sought to determine whether
a simple model depending on residue identity or glycosylation
at a small number of positions could account for a signiﬁcant
portion of the dispersion of neutralization activity across panels
of one hundred to several hundred viral strains. Env positions
identiﬁed by this approach are potentially part of the epitope
for the antibody, and these sites could then be investigated by
site-directed mutagenesis.
Results
We developed a software tool that can be used to organize and
analyze HIV-1 neutralization data, viral and antibody sequences,
and structural information. The data are organized via a relational
data model such that, e.g., an antibody entry is linked to the neu-
tralization assays that have been performed for that antibody (Fig.
S1A). In addition, the antibody entry is linked to its heavy and light
chain protein entries, from which the sequences can be obtained,
and to its Protein Data Bank (PDB) entry (www.rcsb.org/pdb/) if
a crystal structure is available. Similarly, each Env entry is linked
to its neutralization assay results and its sequence. Sequence
alignment position numbering is based on reference sequences
(e.g., HxBc2 numbering for Env sequences). Neutralization data
can be displayed in a table format that can be sorted or shown
along with aligned Env sequences. Potential N-linked glycosyl-
ation sites, as identiﬁed by the Asn–X–Ser/Thr sequon, can be
highlighted, and sequences can be displayed relative to a consensus
sequence (Fig. S1B). Coverage curves, which show the cumulative
frequency of IC50 values up to the concentration shown on the
x axis, can be generated to compare breadth and potencies of
individual antibodies (Fig. S1C).
The primary goal of the program is to uncover correlations by
providing ready access to multiple types of data in a single en-
vironment. Toward this end, the program interface is fully graph-
ical and requires no text commands or scripting. The program can
load a built-in set of published neutralization data on broadly
neutralizing anti–HIV-1 antibodies (currently including ∼10,000
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IC50 measurements for ∼45 antibodies) along with aligned se-
quences for the Env proteins of relevant viral strains [currently
∼500 strains have neutralization data; an alignment with ∼3,000
strains from the Los Alamos HIV Sequence Database (www.hiv.
lanl.gov/) is also included]. The user can input data ﬁles as more
neutralization measurements become available.
Modeling of Neutralization Data. A model was developed for de-
termining which Env sequence features correlate with the dis-
persion in an antibody’s neutralization IC50 values across strains.
The analysis method attempts to minimize the differences be-
tween the experimental IC50 values and modeled IC50 values by
adding sequence-based rules in a stepwise fashion. This process
can be stopped when cross-validation (16) indicates that additional
rules are overﬁtting the available neutralization data. From a set
of potential rules covering the entire Env sequence, a small
number of rules are selected that minimize the difference between
the experimental IC50 values and modeled IC50 values (Model50)
(SI Materials and Methods). For a given antibody, we deﬁne the
dispersion residual R as follows:
R =
X
s∈ Strains
ln

IC50ðsÞ

− ln

Model50ðsÞ
:
The model consists of a set of rules that provide an estimated IC50
based on an Env sequence. Each rule has three aspects as follows:
(i) an Env sequence location (using standard HxBc2 numbering),
(ii) a single amino acid residue or N-linked glycosylation site, and
(iii) a numerical value V (positive or negative) that contributes to
the natural logarithm of the modeled IC50 when the feature spec-
iﬁed by (i) and (ii) is present. The V terms are analogous to
interaction energy terms contributing to the binding free energy
between two molecules. For strain s, we have the following:
lnðModel50ðsÞÞ= baselineopt
+
X# of rules
i
Vi * δ

sequence of s matches rule i

;
where baselineopt is chosen for each set of rules to minimize the
residual R over a set of strains. The baselineopt represents the
invariant net contribution of all other residues to neutralization.
The program examines rules of the type described above for
all Env sequence position/residue combinations and determines
the optimal (for one or two rules) or near-optimal (for three or
more rules) set of rules in a stepwise manner. The numerical
values V are also optimized during this process. To avoid over-
ﬁtting, a portion of the neutralization data (the test set) can be
excluded from the rule optimization process. The user can choose
which rules to use by including rules until the residual of the test
set no longer improves. After ﬁnding an optimal set of rules, the
quality of individual rules (an assessment of the strength of the
association between the rule and the variation of an antibody’s
neutralization potency across strains) is scored based on several
factors: (i) whether there is support for the rule within multiple
clades, (ii) the reduction in residual R attributed to the rule, and
(iii) the fraction of strains for which the rule applies. This is an
indirect means of addressing interfering viral lineage founder
effects (17).
Typical rules sets produced by this analysis are shown in Table 1
for 24 antibodies and soluble CD4 (sCD4). Many Env residues
known to be critical for neutralization by particular antibodies
were identiﬁed; e.g., for antibody 2F5, Env residues 665 and 667
were identiﬁed, which are within the known core epitope of 2F5
within membrane-proximal external region (MPER) residues
662–668 of the glycoprotein gp41 Env subunit (18). Muta-
tion of residue 665 leads to resistance to 2F5 (19), and position
667 has been suggested to also play a role in 2F5 resistance (20).
In addition, for antibody 2G12, the optimized rules set indicates
Table 1. Optimized model rules that attempt to account for the variation in neutralization IC50 values across strains
Antibody Residual Free residual Rules Baselineopt No. of strains
10-996 0.35 0.55 332 #−6.18; 330 H−4.37; 444 S−2.32; 49 D−2.21 8.41 119
10-1074 0.37 0.36 332 #−6.80; 843 V+6.67; 240 S+6.80; 369 I+6.18 4.00 119
8ANC195 0.42 0.52 234 #−4.78; 230 #+2.94; 276 #−4.78 8.82 119
PGT121 0.48 0.52 332 #−7.48; 843 V+7.48; 184 M+7.42; 702 L−3.56; 442 E+5.67 7.30 152
2G12 0.50 0.59 295 #−2.83; 332 #−5.17; 339 #−2.35 10.99 364
2F5 0.51 0.56 667 A−1.94; 665 K−1.59; 640 S−1.10; 518 M−0.74; 350 R+0.66 4.58 386
3BNC55 0.54 0.72 279 D−5.15; 92 E−5.15 3.69 119
VRC-PG04b 0.57 0.87 364 H+6.23; 365 S−5.01; 276 #−4.53; 232 T+1.62; 85 Y+3.53 7.39 155
PG16 0.58 0.73 787 (5) G−2.64; 171 K−4.08; 160 #−5.30; 186 (1) K−4.86; 186 (18) #+5.26 8.16 176
VRC03 0.59 0.83 5 (2) R−5.10; 106 T−3.53; 19 V−5.67 3.95 174
VRC-CH31 0.61 0.93 640 G+6.18; 798 S+4.41 −2.85 60
VRC-PG04 0.61 0.76 364 H+5.15; 365 S−4.30; 106 E+1.84; 276 #−5.26; 403 T+1.32 6.54 155
12A12 0.64 0.93 459 G−5.93; 357 K−1.49; 238 P+1.46; 155 Q+2.94; 719 I−1.32 4.72 119
b12 0.68 0.65 369 L+1.94; 185 D−2.55; 386 #+2.21; 364 S−4.78 5.67 400
PG9 0.69 0.97 732 G+3.53; 160 N−7.42; 171 K−2.02 6.20 202
NIH45-46G54W 0.73 0.74 459 G−7.42; 456 R−7.42; 651 S−2.94 10.86 113
VRC02 0.75 0.78 403 T+1.97; 459 G−4.64; 106 T−1.77; 772 R+1.32; 706 N−2.58 5.01 171
45-46m2 0.76 0.68 456 R−6.18; 459 G−6.18 8.30 114
3BNC117 0.76 0.86 459 G−6.18; 471 E+6.18 4.25 213
10E8 0.79 0.87 231 E+1.49; 693 V−2.02; 301 #+3.64 −4.65 158
VRC01 0.81 0.95 364 H+2.06; 234 #+1.31; 106 T−1.46; 459 G−4.41 2.43 252
NIH45-46 0.84 0.89 459 G−6.18; 234 #+1.47 3.50 224
45-46m7 0.85 0.83 459 G−5.15 2.34 114
4E10 0.97 1.04 683 K−1.10 1.94 386
sCD4 0.97 1.04 364 P+0.74 1.91 372
N-linked glycosylation sites are indicated by a number sign (#). Positive values indicate resistance to neutralization, whereas negative values indicate
increased susceptibility to neutralization. Individual rules are colored by a measure of the quality of support for the rule (green > black > red). Residual values
are given relative to the starting (no rules) residual. Position numbers are listed using HxBc2 numbering, with insertions indicated by parentheses.
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that glycosylation at sites 295, 332, and 339 on the gp120 subunit
of Env are important for neutralization, consistent with pre-
vious mutagenesis and escape studies (21, 22). For VH1-2–derived
CD4-binding site antibodies VRC01, NIH45-46, 12A12, and
3BNC117, a common rule was found indicating that Gly at po-
sition 459 is important for neutralization. This is also consistent
with mutagenesis and escape studies on this class of antibodies
(23, 24). Overall, rules that correspond to known antibody epi-
tope residues were identiﬁed for 14 of 18 distinct antibodies
analyzed (Table S1).
The fraction of the IC50 variability accounted for by the analysis
varied greatly among the antibodies: for glycan-dependent anti-
bodies such as 2G12 (21, 22) and 10-1074 (25), ∼50% of the
variability was modeled, whereas for 4E10, an anti-MPER anti-
body (19) and VRC01, a CD4-binding site antibody (1), less than
20% was modeled. In general, the neutralization data for glycan-
dependent antibodies yielded better models. This may reﬂect the
high degree of variability in Env glycosylation patterns as well as the
near-complete dependence on speciﬁc glycans for such antibodies.
Analysis of an Antibody with an Unknown Epitope.As a test case, we
investigated antibody 8ANC195, whose epitope was unknown.
This antibody was identiﬁed along with a group of CD4-binding
site antibodies by single-cell antigen capture methods using a frag-
ment of the HIV-1 Env as bait (3). An analysis using the Antibody
Database program predicted that three N-linked glycosylation sites
determined 8ANC195 activity: intact potential N-linked glycosyla-
tion sites at Env positions 234 and 276 and the absence of a site
at position 230 were associated with stronger neutralization (Figs.
1 and 2A).
To test these predictions, we initially performed in vitro neu-
tralization assays to evaluate the activity of 8ANC195 against
site-directed mutants of the clade B HIV-1 YU2 strain (Fig. 2B
and Table 2). Mutants to remove the glycan at position 234 (YU2
N234S and YU2 T236K) and at position 276 (YU2 N276S) were
constructed, along with a mutant that introduced a potential glycan
site at position 230 (YU2 D230N/K232T). These mutants were
compared against wild-type YU2 and a control CD4-binding site
mutant (YU2 N280D) for their sensitivity to 8ANC195 IgG.
Removal of the 234 site led to complete resistance, whereas
removal of the 276 site led to a 60-fold increase in IC50. Intro-
duction of a site at position 230 led to a sixfold increase in IC50.
The results were consistent with the model’s predictions of very
strong dependence on the 234 and 276 sites and a more modest,
but opposite, effect of glycosylation at position 230.
As an additional means to test our model, we examined emer-
gence of naturally occurring resistance mutations in response to
8ANC195 antibody therapy in HIV-1YU2–infected humanized
mice (24). Therapy was initiated in chronically HIV-1YU2–infected
mice carrying a diversiﬁed viral swarm as shown by pretreatment
sequence analysis (Fig. 3). 8ANC195 was administered s.c. with
a loading dose of 1 mg followed by 0.5 mg of antibody twice per
week. Viremia decreased only slightly (0.1 log10 after 7 d) and
remained stable after 14 d of treatment (Fig. S2). Consistent with
selection by 8ANC195, virus cloned during treatment had acquired
mutations to remove the potential N-linked glycosylation site at
position 276 in two of three mice from which viral sequences
were obtained (Fig. 3 and Fig. S3).
Evaluating the Glycan Dependence of 8ANC195. To further evaluate
the glycan dependence of 8ANC195, we used surface plasmon
resonance (SPR) to study binding of 8ANC195 to a gp120 core
protein before and after treatment with endoglycosidase H
(Endo H). This enzyme removes accessible N-linked high-mannose
oligosaccharides from glycoproteins such as gp120, although
Endo H treatment is not maximally efﬁcient under nondena-
turing conditions. We found that 8ANC195 Fabs bound to
immobilized untreated gp120 but no binding was detected to
Endo H-treated gp120 (Fig. 4 A and B). Binding to the gp120
core by a glycan-independent control antibody, 3BNC60 (a CD4-
binding site antibody), was not affected by Endo H treatment
(Fig. 4A). Therefore, at least one of the Endo H-sensitive N-linked
glycosylation sites on gp120 is required for binding of 8ANC195.
To evaluate the glycan speciﬁcity of 8ANC195, we tested
binding of gp120 core protein expressed in cell lines that differed
in their glycosylation proﬁles. gp120s expressed in insect cells are
expected to contain only high-mannose N-glycans (26), as are
gp120s expressed in mammalian GnTI−/− cells, an HEK293 cell
line lacking the enzyme N-acetylglucosaminyltransferase I (GnTI)
that is required for processing high-mannose N-glycans to complex-
type N-glycans (27). In contrast, gp120s expressed in HEK293-6E
cells should contain all types of N-glycans, including complex-type,
high-mannose, and hybrid N-glycans. We found that 8ANC195
bound equivalently to gp120 cores expressed in each of these
cell lines and did not bind to Endo H-treated gp120 cores from
insect or HEK293-6E cells, indicating that it does not depend on
complex-type or hybrid N-glycans for binding to gp120 (Fig. 4C).
To further investigate the potential role of complex-type
N-glycans on HIV-1 Env in neutralization by 8ANC195, we created
high-mannose–only virions by producing pseudoviruses in GnTI−/−
Fig. 1. Experimental (red) and predicted (blue) IC50 values for antibody
8ANC195 on a panel of 119 viral strains. The prediction is that glycosylation
at positions 234 and 276 is required for neutralization, whereas glycosylation
at 230 reduces neutralization sensitivity.
Fig. 2. Glycosylation sites affecting 8ANC195 neutralization. (A)
Location of potential N-linked glycosylation sites (red highlights)
on gp120 (gray surface) predicted to affect 8ANC195 neutrali-
zation. For reference, the location of the CD4-binding site epi-
tope on gp120 is illustrated using the structure of an NIH45-
46–gp120 complex (PDB ID code 3U7Y). (B) Neutralization of
HIV-1 strain YU2 and YU2 mutants by 8ANC195 IgG. Mutations
removing glycosylation sites at Env positions 234 or 276 greatly
reduced the neutralization potency of 8ANC195, and addition
of a potential site at position 230 led to a moderate decrease in
potency. A mutation (N280D) near the CD4-binding site on Env
had no effect on 8ANC195 neutralization.
10600 | www.pnas.org/cgi/doi/10.1073/pnas.1309215110 West et al.
HEK293 cells (27, 28). The neutralization potencies of 8ANC195
against normal virions and high-mannose–only virions were similar
(Table S2), consistent with the binding studies suggesting that the
glycan dependence of 8ANC195 was not speciﬁc to complex-
type N-glycans.
Taken together with the neutralization assay results, the binding
studies suggest that 8ANC195 recognizes HIV-1 by a mechanism
that requires high-mannose N-glycans, or the core pentasaccharide
common to all types of N-glycans, attached to Asn234 and Asn276.
Discussion
Recent advances in identiﬁcation of antibodies from HIV-1–
infected humans has resulted in many promising antibodies with
broadly neutralizing activity (reviewed in ref. 29). These anti-
bodies were reported along with a wealth of neutralization data
against broad panels of primary HIV-1 strains; e.g., ∼2,500 IC50
values covering >80 antibodies were presented in two papers
describing antibodies against the CD4 binding site on HIV-1 Env
(3, 4). Information regarding antibody recognition of HIV-1 can
be deduced from the neutralization data and the sequences of
HIV-1 Env; however, extracting such information manually can
be prohibitive in terms of time and effort. A recent analysis of
neutralization panel data has been used to cluster antibodies
based on similar patterns of neutralization (30), and this approach
can be used to deconvolute the neutralizing activities present in
polyclonal sera. Although antibody 8ANC195 was noted to form
a distinct cluster, no speciﬁc viral epitope was identiﬁed. Here, we
report a program, Antibody Database, that analyzes anti–HIV-1
antibody potencies and breadth systematically to deduce the iden-
tities of Env residues required for neutralization.
The program identiﬁed known critical residues on Env recog-
nized by well-characterized antibodies and uncovered an epitope
recognized by 8ANC195, a potent broadly neutralizing antibody
whose epitope was not known (3). The 8ANC195 example illus-
trates how the computational results are intended to be used, i.e.,
for design of experiments to identify residues responsible for an-
tibody potency variability across viral strains. Our approach does
not attempt to establish the statistical signiﬁcance of the corre-
lations that are identiﬁed because the assumptions necessary to
assign probabilities to the output of the model are themselves
uncertain. Instead, we use the analysis as a part of a heuristic ap-
proach to identifying an antibody’s functional epitope. By “func-
tional epitope,” we refer to those residues, which when mutated,
exert a major effect upon the binding afﬁnity and neutralization
activity. In general for protein–protein interactions, a functional
epitope is deﬁned as those residues for which ΔΔG > 2 kcal/mol
for substitution of a single amino acid to alanine, as distinguished
from a structural epitope (all residues at the protein–protein in-
terface) (31). The functional epitope residues identiﬁed by our
analysis are often associated with variations leading to resistance
to a given antibody (e.g., Env position 276 for 8ANC195). A notable
feature of these results compared with other approaches (such as an
alanine scanning mutagenesis) is that variations at functional sites
are likely resistance mutations of antibody-sensitive strains because
these variations are known to give rise to viable virus.
The simplifying assumption that neutralization data can be
modeled by independent rules is best supported when (i) neu-
tralization potency correlates with antibody binding to Env, and
(ii) binding is not accompanied by conformational changes in
antibody or Env. In this situation, one may expect relatively in-
dependent contributions to neutralization or binding corresponding
to individual interactions between antibody and Env. This would
not be complete independence; e.g., substitution at the antibody/
Env interface of a small residue by a large residue may require
a shift of the two molecules that would disrupt other interactions.
When the two conditions above are not satisﬁed (i.e., neutrali-
zation does not correlate with binding and the effect of a varia-
tion in sequence at one location is contingent on the sequence at
other locations), independent contributions are not necessarily
expected. Indeed, for reagents such as soluble CD4 that induce a
large conformational change in Env upon binding (32), very little
of the variability in neutralization potency across strains can
be modeled by this simple approach (Table 1). Nevertheless, the
rules analysis may be justiﬁed as an empirical method if it is
found that predicted rules correspond to experimentally determined
critical residues.
Our sequence-based approach to deducing rules for neutraliza-
tion has limitations. For example, critical antibody epitope residues
on HIV-1 Env that are very highly conserved across a viral panel
will not be identiﬁed in this approach because the ability to rec-
ognize a critical residue depends on variation in the residue
identity being correlated with IC50 differences. A greater prob-
lem is that phylogenetic linkage between Env sites (a viral lineage
founder effect) (17) can generate spurious rule predictions. As a
consequence, the results of an analysis must be considered ten-
tative and are best used as a means to identify candidate epitope
residues for further investigation. The program partially takes
founder effects into account postoptimization by assigning a qual-
ity score to individual rules based on whether there is independent
multiclade support for a rule (as well as other factors, such as the
Table 2. Neutralization IC50 values of YU2 and YU2 mutants by
8ANC195 IgG and CD4-binding site antibody NIH45-46G54W
Pseudovirus
Glycosylation
mutant
8ANC195
IC50, μg/mL
NIH45-46G54W
IC50, μg/mL
YU2 wt 0.53 0.003
YU2 N280D wt 0.79 >50
YU2 N234S Remove 234 >50 0.025
YU2 T236K Remove 234 >50 <0.001
YU2 N276S Remove 276 32 0.003
YU2 D230N/K232T Add 230 3.3 0.001
Fig. 3. Individual gp120 envelope sequences cloned
from single mice (y axis; mouse numbers indicated
on the Right) before and after 8ANC195 therapy.
gp120 sequences are represented by the light gray
horizontal bars with silent mutations indicated in
green and amino acid replacements in red. Posi-
tion 276 is indicated by the blue-gray vertical bar.
All mutations are relative to HIV-1YU2 and num-
bered according to the HxBc2 strain of HIV-1. No
Env sequences could be obtained from mouse
604 or mouse 726.
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residual reduction due to a particular rule). In an earlier statistical
study (9), the founder effect problem was systematically taken into
account using a phylogenetic analysis approach, although this in-
volved scoring each viral strain in a binary fashion as either neu-
tralization sensitive or neutralization resistant. In contrast, the rule
set analysis used in our approach takes into account the full vari-
ability, from weakly to strongly neutralizing, in the neutralization
panel. Thus, at the cost of having to manually assess potential
founder effects by examining effects in individual clades, the
rules approach used here offers the potential to identify features
that have either modest or strong contributions to the variation
in potency.
Our approach includes a method of statistical cross-validation
to avoid overﬁtting the available neutralization data as could occur
by addition of too many rules. Toward this end, the neutralization
data are split into a working set used for rule ﬁnding/optimization
and a test set for validation of the rules. The residual of the test set
is analogous to the crystallographic Rfree value (16), which is cal-
culated on a subset of data that are not used during reﬁnement of
the model. When too many parameters are reﬁned in crystal-
lographic reﬁnement, the Rfree will remain the same or become
larger even when the working set R value is reduced. Likewise,
the residual of the test set in the reﬁnement of the neutrali-
zation model should rise when false rules are added.
The potential utility of our approach was illustrated by ﬁnding
an epitope on HIV-1 Env for the broadly neutralizing antibody
8ANC195. Our computational analysis suggested that the
neutralization activity of 8ANC195 is dependent on N-linked gly-
cans attached to Env residues Asn234 and Asn276, which was
veriﬁed experimentally in vitro and in vivo. These glycosylation sites
are distinct from those that affect other known glycan-dependent
anti–HIV-1 antibodies: 2G12 (glycans attached to Env positions
295, 332, 339, 386, 392, and 448) (21, 22), PG9/PG16 (position
160) (2), PGT121/10-1074 and PGT128 (positions 332 and 301)
(5, 25). Consistent with their identiﬁcation as part of the 8ANC195
epitope, residues 234, 276, and 230 are on one face of gp120. Two
of the glycans within the proposed 8ANC195 epitope, the Asn234-
and Asn276-attached glycans, approach each other closely (Fig.
2A). Indeed, based on the glycans observed in the crystal struc-
ture of a gp120 complexed with the CD4-binding site antibody
45-46m2 (33), the acetyl groups of the Asn-linked N-acetyl glu-
cosamine moieties of the 234 and 276 sites are within ∼3.5 Å.
The breadth of 8ANC195 against HIV-1 strains (3) is explained
by the Asn234 and Asn276 N-glycan sites being relatively common
in HIV-1 strains: 81% and 95% of 2,869 sequences from the Los
Alamos HIV-1 sequence database have potential N-glycosylation
sites at positions 234 and 276, respectively. Potential N-linked
glycosylation is less frequent at position 230 (34%), the site that
appears to reduce neutralization sensitivity to 8ANC195.
There are strains whose sensitivity to 8ANC195 is not correctly
predicted by the glycosylation pattern found by our analysis; e.g.,
HIV-1 strain R2184.C4 lacks glycosylation at 234 and would thus
be expected to be resistant to 8ANC195, but this strain is one of
the most sensitive (in Fig. 1, R2184.C4 is the viral strain second
from the left). Although this strain lacks a glycosylation site at
Env position 234, it has a potential N-linked glycosylation site
at position 232 and is the only strain in the 8ANC195 neutrali-
zation panel with this potential site. Hence, we suggest that, for
8ANC195 neutralization, a glycan at site 232 can substitute for
an adjacent glycan at site 234.
Analysis of 8ANC195, a potent broadly neutralizing antibody
that targets a previously unknown epitope on the HIV-1 Env,
uncovered a site of vulnerability on HIV-1 and potentially a target
for vaccine development. The epitope involving two N-linked Env
glycans is adjacent to the CD4-binding site on Env (Fig. 2 A), but
distinct from that epitope because an Env mutation (N280D)
affecting neutralization by potent VRC01-like CD4-binding
site antibodies (23) did not affect neutralization by 8ANC195
(Fig. 2B). We conclude that computational analysis of neu-
tralization panel data provides a rapid means for identiﬁcation
of functional epitope residues by generating testable hypotheses
using data routinely collected on newly identiﬁed neutralizing
antibodies.
Materials and Methods
Computational Analysis. An antibody and virus database and analysis pro-
gram was written in Objective-C as a Cocoa application for Mac OS X 10.7
and higher. The database aspect of the program uses the Core Data object
graph and persistence framework. Published neutralization panel data
(1, 3–5, 25, 34–36) is built in to the program, and additional neutralization
data can be loaded from ﬁles in comma-separated values format. Sequences
of Env from commonly used HIV-1 strains and from the Los Alamos HIV
Sequence Database are also built in. HIV-1 envelope sequences were aligned
based on DNA sequences using the Gene Cutter tool at www.hiv.lanl.gov/
content/sequence/GENE_CUTTER/cutter.html. The executable program and
the source code for the rule-ﬁnding component are available upon request.
For calculations of the dispersion residual R, when an IC50 is known only
to be greater than or less than some value (e.g., >50 μg/mL), then that value
is used as the experimental IC50. When model or experimental IC50 values
are above a user-adjustable cutoff value (usually 50 μg/mL), the ﬁtting
procedure treats these values as equal to the cutoff value.
When the number of neutralization resistant strains is greater than 50%
of the total strains, the dispersion residual R sum over strains is weighted
in favor of the sensitive strains (such that the sensitive strains account for
60% of the starting residual). A fraction (20%) of the panel can be excluded
from the rule set optimization process for cross-validation in a manner analo-
gous to calculation of the Rfree value in crystallography (16). The set of strains
that are excluded is chosen randomly; thus, repeated-analysis runs on the same
antibody neutralization dataset will be produce slightly different results.
The rule-ﬁnding process begins with all Env positions and all residues
(and glycosylation), with a user-adjustable cutoff value m (default 5%) that
eliminates rules that apply to less than that fraction or more than the
fraction 1 − m of viral strains. During initial screening, rule Vi values from
0.74 to 5.15 (and from −0.74 to −5.15) in steps of 0.37 are tested. This cor-
responds to rules that would cause a 2-fold to 172-fold difference in IC50.
Rule parameters are optimized by a combination of grid search and grid
walk methods. During each round of rule addition, all rule Vi values can
be increased or decreased by 10% or 20%. Additional rules are added in
a stepwise fashion, choosing the new rule that yields the lowest R value.
Fig. 4. SPR binding studies evaluating the glycan dependence of 8ANC195.
(A) Effect of Endo H treatment of gp120 on binding of injected 8ANC195 Fab
(Left) or 3BNC60 Fab (Right) to immobilized 93TH057 gp120 core. 8ANC195
bound to untreated gp120 core (dark blue) but not Endo H-treated gp120
core (light blue), whereas 3BNC60 bound to both untreated (dark green) and
Endo H-treated (light green) gp120 core. (B) SDS/PAGE analysis of 93TH057
gp120 core expressed in Hi5 insect cells (lanes 1 and 2) and HEK293-6E cells
(lanes 3 and 4) before and after Endo H treatment. Gels were stained with
Coomassie Blue. (C) Binding of gp120 cores expressed in different cell lines
injected over immobilized 8ANC195 Fab. Untreated gp120 cores expressed in
Hi5 insect cells (dark blue), GnTI−/− cells (green), and HEK293-6E cells (purple)
bound to 8ANC195 Fab, but Endo H-treated gp120 cores from Hi5 insect cells
(light blue) and HEK293-6E cells (pink) did not bind.
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A list of the top rules sets at each step is stored, so that lower-ranked
solutions can be examined.
Mutagenesis. QuikChange mutagenesis was used to generate gp160 mutants.
All gene constructs were veriﬁed by complete sequencing.
Protein Expression and Puriﬁcation. Antibodies were transiently expressed
in HEK293T/17 cells or suspension HEK 293-6E cells (National Research Council
Biotechnology Research Institute, Montréal, QC, Canada) using 25-kDa linear
polyethylenimine (Polysciences) for transfection as described in refs. 37 and 38.
Supernatants were passed over MabSelect SuRe protein A resin (GE Health-
care) or Protein G Sepharose 4 Fast Flow (GE Healthcare) and eluted by using
pH 3.0 citrate or glycine buffer, and then immediately neutralized. Antibodies
tested in neutralization or binding assays were further puriﬁed by size ex-
clusion chromatography using a Superdex 200 or 75 10/300 GL column. For SPR
experiments, 8ANC195 and 3BNC60 IgGs were cleaved with papain to gener-
ate Fabs as described (36). A clade A/E 93TH057 gp120 core containing trun-
cations in the N and C termini and loops V1–V2 and V3 was produced as
described above using HEK 293-6E, GnTI−/−, or in baculovirus-infected Hi5 in-
sect cells (36), followed by puriﬁcation using a Ni2+-nitrilotriacetic acid column
and Superdex 200 16/60 size exclusion chromatography (GE Healthcare). Endo
H treatment of gp120 was done by incubating gp120s with 20 kU of Endo H
(New England Biolabs) per 1 mg of gp120 at room temperature for 16 h,
followed by size exclusion chromatography puriﬁcation.
In Vitro Neutralization Assays. A TZM-bl/pseudovirus neutralization assay was
used to evaluate the neutralization potencies of the antibodies as described
in refs. 13 and 36, and described in detail in SI Text.
Antibody in Vivo Experiments. Humanized mice were generated as described
(24). Brieﬂy, 1- to 5-d-old NOD Rag1−/−Il2rγnull mice (The Jackson Laboratory)
were irradiated with 100 cGy and injected intrahepatically with 0.15–2 × 106
hematopoietic stem cells obtained from fetal livers that were procured from
Advanced Bioscience Resources. Mice used in 8ANC195 experiments were
chronically infected with HIV-1YU2 and subjected to s.c. antibody injections.
8ANC195 was in 1× PBS and sterile ﬁltered shortly before administration.
Mice received a loading dose of 1 mg followed by 0.5 mg of antibody twice
per week. All mice were maintained at The Rockefeller University Comparative
Bioscience Center and handled according to the guidelines by the Institutional
Animal Committee. Experiments were performed with authorization from the
Institutional Review Board and the Institutional Animal Care and Use Com-
mittee at The Rockefeller University. Viral load measurement and gp120
sequence analysis was done as described (24).
SPR. A Biacore T100 (GE Healthcare) was used to evaluate the interac-
tions of 8ANC195 with Env proteins. For experiments comparing binding
of 8ANC195 and 3BNC60 Fabs to gp120 cores, ∼1,500 response units (RU) of
untreated or Endo H-treated 93TH057 gp120 core was covalently immobilized
on three ﬂow cells of a CM5 biosensor chip using standard primary amine
coupling chemistry (Biacore manual). 8ANC195 Fab or 3BNC60 Fab were injec-
ted at 500 nM concentration in 10 mM Hepes with 150 mM NaCl, 3 mM EDTA,
and 0.05% surfactant P20 at pH 7.4 at room temperature. For experiments
comparing binding of 8ANC195 to gp120 cores expressed in different cell lines,
∼1,000 RU of 8ANC195 Fab was covalently immobilized using standard primary
amine coupling chemistry. 93TH057 gp120 cores from Hi5 insect cells, GnTI−/−
cells, or HEK293-6E cells, as well as Endo H-treated gp120 cores from Hi5
insect cells and HEK293-6E cells were injected at 1 μM concentration.
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